-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, Fate Therapeutics announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that it announced its research on natural killer cell (NK cell) therapy FT516, combined with rituximab to treat relapse/refractory Data from an active phase 1 clinical trial in patients with sexual B-cell lymphoma
.
FT516 is the company's "ready-to-use" natural killer cell in research therapy derived from a cloned induced pluripotent stem cell (iPSC) line
.
It uses a novel high-affinity, non-cleavable CD16Fc receptor, designed to maximize antibody-dependent cell-mediated cytotoxicity (ADCC)
.
As of March 11, 2021, a total of 11 patients can be used for safety and efficacy assessment
.
The test results showed that 8 out of 11 patients achieved objective remission, including 6 patients achieved complete remission
.
These patients have received an average of 3 pre-treatments in the past, and 4 of them have previously received autologous CD19 CAR-T cell therapy
.
Image source: Reference materials [1] In terms of safety, no dose-limiting toxicity was found, no serious adverse events related to FT516 and adverse events of grade 3 or higher related to FT516 were found
.
"These phase 1 clinical trial data from outpatient administration of FT516 continue to demonstrate its differentiated safety characteristics and its potential clinical benefits
.
"Fate Therapeutics Senior Vice President of Clinical Development Dr.
Wayne Chu said, "Based on FT516's continued favorable therapeutic properties and the potential to treat patients on demand without delay, we plan to initiate multiple dose expansion cohorts for patients with B-cell lymphoma.
To evaluate the potential of FT516 combined with CD20-targeted monoclonal antibody as a pre-treatment
.
"Reference: [1] Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting.
Retrieved June 7, 2021, from https://ir.
fatetherapeutics.
com/news-releases/news-release-details/fate-therapeutics-highlights-positive-interim-data-its-phase-1 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need a treatment plan For guidance, please go to a regular hospital for treatment
.
.
FT516 is the company's "ready-to-use" natural killer cell in research therapy derived from a cloned induced pluripotent stem cell (iPSC) line
.
It uses a novel high-affinity, non-cleavable CD16Fc receptor, designed to maximize antibody-dependent cell-mediated cytotoxicity (ADCC)
.
As of March 11, 2021, a total of 11 patients can be used for safety and efficacy assessment
.
The test results showed that 8 out of 11 patients achieved objective remission, including 6 patients achieved complete remission
.
These patients have received an average of 3 pre-treatments in the past, and 4 of them have previously received autologous CD19 CAR-T cell therapy
.
Image source: Reference materials [1] In terms of safety, no dose-limiting toxicity was found, no serious adverse events related to FT516 and adverse events of grade 3 or higher related to FT516 were found
.
"These phase 1 clinical trial data from outpatient administration of FT516 continue to demonstrate its differentiated safety characteristics and its potential clinical benefits
.
"Fate Therapeutics Senior Vice President of Clinical Development Dr.
Wayne Chu said, "Based on FT516's continued favorable therapeutic properties and the potential to treat patients on demand without delay, we plan to initiate multiple dose expansion cohorts for patients with B-cell lymphoma.
To evaluate the potential of FT516 combined with CD20-targeted monoclonal antibody as a pre-treatment
.
"Reference: [1] Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting.
Retrieved June 7, 2021, from https://ir.
fatetherapeutics.
com/news-releases/news-release-details/fate-therapeutics-highlights-positive-interim-data-its-phase-1 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need a treatment plan For guidance, please go to a regular hospital for treatment
.
